ProQR Therapeutics presented new data on its Axiomer RNA editing technology at Deaminet 2024, showing up to 70% editing efficiency in non-human primates and mice. The platform also demonstrated a functional effect in mice, with modulation of ANGPLT3 protein properties leading to an increase in LPL activity and a significant impact on biomarkers. Further data for pipeline programs AX-0810 and AX-1412 will be presented throughout 2024.